Earlier this week, a Phase 2 study of extended-release ketamine tablets for treatment-resistant depression (TRD) published in Nature Medicine (Glue et al., 2024). The study (dubbed BEDROC; ACTRN12618001042235) was sponsored by Douglas Pharmaceuticals, a New Zealand-based drug manufacturer, which is developing the 60mg ketamine tablets under the moniker R-107.
